title: Selecting targeted therapies for patients with renal cell carcinoma.
abstract: Advanced renal cell carcinoma (RCC) is a heterogeneous disease with variable histology, biology, and response to treatment. In the past 5 years, 6 new agents have been approved for the treatment of RCC, and many more are in clinical development. With an ever-increasing number of treatment options, selecting among them for a particular patient can be a daunting task for clinicians. This article describes how treatment choice can be guided by the disease setting and histology, as well as patient characteristics, comorbidities, and preference within the context of available data. Results from clinical trials are combined with practical considerations to make recommendations for first-line and subsequent treatment of patients with clear cell and non-clear cell RCC. These recommendations should supplement the current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of advanced RCC.
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497, USA. elizabeth.plimack@fccc.edu
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Plimack
authors.forename: Gary R
authors.initials: GR
authors.lastname: Hudes
mesh_terms: D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D016896:Treatment Outcome